{"id":"NCT00477633","sponsor":"Warner Chilcott","briefTitle":"Study of Safety and Efficacy of an Oral Contraceptive","officialTitle":"An Open Label Study of the Contraceptive Efficacy of Norethindrone and Ethinyl Estradiol.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2009-01","completion":"2009-02","firstPosted":"2007-05-24","resultsPosted":"2011-01-24","lastUpdate":"2013-04-22"},"enrollment":1700,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Contraception"],"interventions":[{"type":"DRUG","name":"Norethindrone/ethinyl estradiol","otherNames":[]}],"arms":[{"label":"Norethindrone/ethinyl estradiol","type":"EXPERIMENTAL"}],"summary":"This is a non-comparative study. the primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding; and to assess the safety and tolerability of the product.","primaryOutcome":{"measure":"Pearl Index, 18-35 Years, MITT Population","timeFrame":"13 cycles (28 days each), approximately 364 days","effectByArm":[{"arm":"Norethindrone/Ethinyl Estradiol Tablets","deltaMin":1.903,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":63,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":1677},"commonTop":["Upper Respiratory Tract Infection","Nasopharyngitis","Nausea","Sinusitis","Headache"]}}